The targeted delivery of therapeutics is considered the Holy Grail for treatment of diseases such as cancer and viral infections with the need to selectively treat infected/abnormal cells while sparing normal cells and avoiding toxicity. There is a significant body of literature that supports the observation of abnormal iron metabolism in multiple types of stressed cells. This appears to be associated with an increase in cell surface transferrin (TRF) receptors to support the increased intracellular demand for iron which in turn supports rapid cell division and replication. This observation of increased iron demand has been made in multiple tumor types as well as a range of virus and parasite-infected cells.
Curadox BioPharma, Inc. has developed CB-TD1, a novel drug candidate that capitalizes on these observations and the desire to target only those abnormal cells with an increased iron demand. The drug, intended for intravenous administration, is a conjugate compound that utilizes readily available and well-characterized drug substances in an easily reproduced, low cost and stable manufacturing process.